Citations

Clear

2416 citation(s) found for "Yu, Jason".

Bronchiolar Adenoma
Borsu, Laetitia , Lu, Shaohua, Larsen, Brandon T. , Sae‐Ow, Wichit, Mackinnon, Alexander C. , Bowman, Anita S. , Arcila, Maria E. , Ladanyi, Marc , Chang, Jason C. , Montecalvo, Joseph , Wallace, William D. , Kim, Hyunjae Ryan , Sauter, Jennifer L. , Travis, William D. , Rekhtman, Natasha

Mayo Clinic

American Journal of Surgical Pathology | May 24, 2018 | Volume: 42 | Issue: 8 | Pages: 1010-1026

10.1097/pas.0000000000001086 | PMID 29846186 Get It

We have identified 25 lesions involving alveolar lung parenchyma characterized by nodular proliferation of bland bilayered bronchiolar-type epithelium containing a continuous layer of basal cells. These lesions shared some histologic features with the recently described entity of ciliated muconodular papillary tumor (CMPT); however, the majority did not fit all diagnostic criteria in that they exhibited only focal or absent papillary architecture, and they had variable number of ciliated and mucinous cells, with some lesions entirely lacking 1 or both of these components. The morphologic and immunohistochemical features ranged from those resembling proximal bronchioles (proximal-type: moderate to abundant mucinous and ciliated cells; negative or weak TTF1 in luminal cells; n=8) to those resembling respiratory bronchioles (distal-type: scant or absent mucinous and ciliated cells; positive TTF1 in luminal cells; n=17). The hallmark of all lesions was a continuous layer of basal cells (p40 and CK5/6-positive). We provisionally designated these lesions as bronchiolar adenomas (BAs) and analyzed their clinicopathologic and molecular features. All BAs were discrete, sharply circumscribed lesions with a median size of 0.5 cm (range, 0.2 to 2.0 cm). Most lesions were either entirely flat (n=14) or contained focal papillary architecture (n=7); only 4 lesions, all proximal-type, were predominantly papillary, fitting the classic description of CMPT. Notably, of 9 lesions submitted for frozen section evaluation, 7 were diagnosed as adenocarcinoma. No postsurgical recurrences were observed for any lesions (median follow-up, 11 mo). Twenty-one BAs underwent next-generation sequencing and/or immunohistochemistry for BRAF V600E, revealing mutation profiles similar to those previously described for CMPTs, including BRAF V600E mutations (n=8, 38%), unusual EGFR exon 19 deletions (n=2, 10%), EGFR exon 20 insertions (n=2, 10%), KRAS mutations (n=5, 24%), and HRAS mutations (n=1, 5%). The mutation profiles were similar in proximal-type and distal-type lesions. In conclusion, we describe a family of putatively benign clonal proliferations with a spectrum of morphology recapitulating various levels of the bronchiolar tree, of which only a minor subset fits the classic description of CMPT. Comparable mutation profiles and partially overlapping morphologic features across the spectrum of these lesions support their nosological relationship. We propose designating this entire family of lesions as BAs, and that lesions currently designated CMPTs represent a subgroup of this family.
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients
Doles, Jason D. , Hogan, Kelly A. , O’Connor, Jennifer M. , Hendrickson, Andrea E. Wahner , Huston, Olivia, Jatoi, Aminah , O'Connor, Jennifer, Wahner Hendrickson, Andrea E, Doles, Jason D

Mayo Clinic

Journal of Palliative Medicine | May 24, 2018 | Volume: 21 | Issue: 9 | Pages: 1334-1338

10.1089/jpm.2018.0023 | PMID 29792535 Get It

Biomaterial characterization of off-the-shelf decellularized porcine pericardial tissue for use in prosthetic valvular applications
Choe, Joshua A. , Jana, Soumen , Tefft, Brandon J. , Hennessy, Ryan S., Go, Jason L. , Morse, David , Go, Jason, Young, Melissa D , Morse, David , Lerman, Amir

Mayo Clinic

Journal of Tissue Engineering and Regenerative Medicine | May 11, 2018 | Volume: 12 | Issue: 7 | Pages: 1608-1620

10.1002/term.2686 | PMID 29749108 Get It

Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer
Matsuo, Koji , Mariani, Andrea , Mandelbaum, Rachel S. , Gostout, Bobbie S., Roman, Lynda D. , Machida, Hiroko , Glaser, Gretchen E., Roman, Lynda D , Glaser, Gretchen , Wright, Jason Dennis

Mayo Clinic

Journal of Gynecologic Oncology | May 9, 2018 | Volume: 29 | Issue: 5 | Pages: No page available

10.3802/jgo.2018.29.e69 | PMID 30022633 Get It

Radiological Management of Angiographically Negative, Spontaneous Intracranial Subarachnoid Hemorrhage: A Multicenter Study of Utilization and Diagnostic Yield
Sadigh, Gelareh , Menon, Ranjith K., Bhojak, Maneesh , Aladi, Abather, Mossa‐Basha, Mahmud , Wu, Lei , Brinjikji, Waleed , Dehkharghani, Seena , Derakhshani, Ahrya , Mossa-Basha, Feras, Lehman, Vance T. , Mossa-Basha, Mahmud , Allen, Jason W.

Mayo Clinic

Neurosurgery | April 30, 2018 | Volume: 85 | Issue: 1 | Pages: 126-133

10.1093/neuros/nyy225 | PMID 29850838 Get It

Abstract BACKGROUND The optimal diagnostic evaluation for patients with angiographically negative subarachnoid hemorrhage (AN-SAH) remains controversial. OBJECTIVE To assess the utilization rate and diagnostic yield of imaging tests routinely obtained in identifying a structural cause for AN-SAH. METHODS In this retrospective multicenter study, consecutive adult patients admitted with nontraumatic, AN-SAH between 01/2010 and 12/2015 were included. Patients with intraparenchymal, subdural, or epidural hematomas in addition to SAH were excluded. Outcomes studied included utilization rate, diagnostic yield, and median time from admission for the following imaging tests: initial computed tomography angiography (CTA) and digital subtraction angiography (DSA), brain and cervical spine magnetic resonance imaging (MRI), and any repeat DSA or CTA performed either during initial admission or at long-term follow-up. RESULTS A total of 752 patients were included (mean age, 53 yr; 54% male). Initial CTA and DSA were performed in 89% and 100% of patients, respectively. Brain MRI was performed in 75% of patients and was positive in 0.7% of cases. Cervical spine MRI was performed in 61% of patients and was positive in 0.2% of cases. Repeat, same-admission follow-up DSA and CTA were performed in 48% and 51% of patients and were positive in 3.3% and 1% of cases, respectively. Delayed follow-up DSA and CTA after discharge were performed in 26% and 7% of patients and were positive in 2% and 3.7% of cases, respectively, all with negative prior imaging studies. CONCLUSION Cervical spine and brain MRI have extremely low diagnostic yield, both are commonly utilized in patients with AN-SAH; while repeat DSA and CTA are utilized less commonly and have slightly higher diagnostic yield.
Use of a Knotless Suture Anchor to Perform Double‐Pulley Capsulotenodesis of Infraspinatus
Ratner, Drew A., Rogers, Jason P., Tokish, John M.

Mayo Clinic

Arthroscopy Techniques | April 16, 2018 | Volume: 7 | Issue: 5 | Pages: No page available

10.1016/j.eats.2017.12.002 | PMID 29868423 Get It

Abstract In this Technical Note, we describe an arthroscopic remplissage procedure to treat anterior instability. Specifically, we use a technique to perform double‐pulley capsulotenodesis of the infraspinatus tendon using a Knotless SutureTak Suture Anchor (Arthrex, Naples, FL). This is a modification of a previously described double‐pulley technique. The primary advantage of our technique compared with the previous double‐pulley techniques described is that knot tying is not required. Technique Video video See video under supplementary data.
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
West, Diana C., Kocherginsky, Masha , Tonsing-Carter, Eva , Dolcen, Deniz Nesli , Hosfield, David J., Lastra, Ricardo R. , Sinnwell, Jason P. , Bowie, Kathleen R. , Skor, Maxwell N., Pierce, Charles F., Styke, Sarah C., Kim, Caroline R. , Wet, Larischa de, Wang, Liewei , Győrffy, Balázs , Conzen, Suzanne D. , Thompson, Kevin J. , Greene, Geoffrey L , Sinnwell, Jason P , Harkless, Ryan V. , Boughey, Judy C. , Goetz, Matthew P. , Kalari, Krishna R. , Fleming, Gini F. , Győrffy, Balázs

Mayo Clinic

Clinical Cancer Research | April 10, 2018 | Volume: 24 | Issue: 14 | Pages: 3433-3446

10.1158/1078-0432.ccr-17-2793 | PMID 29636357 Get It

Abstract Purpose: Although high glucocorticoid receptor (GR) expression in early-stage estrogen receptor (ER)-negative breast cancer is associated with shortened relapse-free survival (RFS), how associated GR transcriptional activity contributes to aggressive breast cancer behavior is not well understood. Using potent GR antagonists and primary tumor gene expression data, we sought to identify a tumor-relevant gene signature based on GR activity that would be more predictive than GR expression alone. Experimental Design: Global gene expression and GR ChIP-sequencing were performed to identify GR-regulated genes inhibited by two chemically distinct GR antagonists, mifepristone and CORT108297. Differentially expressed genes from MDA-MB-231 cells were cross-evaluated with significantly expressed genes in GR-high versus GR-low ER-negative primary breast cancers. The resulting subset of GR-targeted genes was analyzed in two independent ER-negative breast cancer cohorts to derive and then validate the GR activity signature (GRsig). Results: Gene expression pathway analysis of glucocorticoid-regulated genes (inhibited by GR antagonism) revealed cell survival and invasion functions. GR ChIP-seq analysis demonstrated that GR antagonists decreased GR chromatin association for a subset of genes. A GRsig that comprised n = 74 GR activation-associated genes (also reversed by GR antagonists) was derived from an adjuvant chemotherapy-treated Discovery cohort and found to predict probability of relapse in a separate Validation cohort (HR = 1.9; P = 0.012). Conclusions: The GRsig discovered herein identifies high-risk ER-negative/GR-positive breast cancers most likely to relapse despite administration of adjuvant chemotherapy. Because GR antagonism can reverse expression of these genes, we propose that addition of a GR antagonist to chemotherapy may improve outcome for these high-risk patients. Clin Cancer Res; 24(14); 3433–46. ©2018 AACR.
HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome
Natesampillai, Sekar, Cummins, Nathan W. , Nie, Zilin , Sampath, Rahul , Baker, Jason V. , Henry, Keith , Pinzone, Marilia Rita , O’Doherty, Una , Bren, Gary D., Katzmann, David J. , Badley, Andrew D. , Polley, Eric C. , Cummins, Nathan W , Badley, Andrew D , O’Doherty, Una

Mayo Clinic

Journal of Virology | April 10, 2018 | Volume: 92 | Issue: 13 | Pages: No page available

10.1128/jvi.00037-18 | PMID 29643240 Get It

ABSTRACT HIV protease is known to cause cell death, which is dependent upon cleavage of procaspase 8. HIV protease cleavage of procaspase 8 generates Casp8p41, which directly binds Bak with nanomolar affinity, causing Bak activation and consequent cell death. Casp8p41 can also bind Bcl2 with nanomolar affinity, in which case cell death is averted. Central memory CD4 T cells express high levels of Bcl2, possibly explaining why those cells do not die when they reactivate HIV. Here, we determine that the Casp8p41-Bcl2 complex is polyubiquitinated and degraded by the proteasome. Ixazomib, a proteasome inhibitor in clinical use, blocks this pathway, increasing the abundance of Casp8p41 and causing more cells to die in a Casp8p41-dependent manner. IMPORTANCE The Casp8p41 pathway of cell death is unique to HIV-infected cells yet is blocked by Bcl2. Once bound by Bcl2, Casp8p41 is polyubiquitinated and degraded by the proteasome. Proteasome inhibition blocks degradation of Casp8p41, increasing Casp8p41 levels and causing more HIV-infected cells to die.
Histopathology of granulomatous liver disease
Lewis, Jason

Mayo Clinic

Clinical Liver Disease | April 10, 2018 | Volume: 11 | Issue: 3 | Pages: 77-80

10.1002/cld.695 | PMID 30992794 Get It

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, Clifford R. , Bennett, David A. , Blennow, Kaj , Carrillo, María C. , Dunn, Billy , Haeberlein, Samantha Budd , Jagust, William J. , Jessen, Frank , Karlawish, Jason , Liu, Enchi , Montine, Thomas J. , Phelps, Creighton H., Rankin, Katherine P. , Scheltens, Philip , Siemers, Eric , Snyder, Heather M. , Contributors, Elliott, Cerise, Masliah, Eliezer , Ryan, Laurie, Silverberg, Nina, Bennett, David A. , Jack, Clifford R , Scheltens, Philip , Holtzman, David M. , Molinuevo, José Luís , Rowe, Christopher Cleon , Sperling, Reisa Anne , Contributors

Mayo Clinic

Alzheimer's & Dementia | April 10, 2018 | Volume: 14 | Issue: 4 | Pages: 535-562

10.1016/j.jalz.2018.02.018 | PMID 29653606 Get It

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a “research framework” because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six‐stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker‐based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker‐based research should not be considered a template for all research into age‐related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that β‐amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.